Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s): CPHRF

Healthcare

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, and Vaniqa. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. It also has the Natroba operations and global product rights to Natroba and its authorized generic Spinosad, a topical treatment for both head lice and scabies.

TSX:CPH - Post by User

Cipher Pharmaceuticals Inc > Profitable Debt-Free Cash-Rich CPH at 0.8x its EBITDA!!!

<< Previous

Bullboard Posts

Next >>

Comment by r0naldon Mar 19, 2021 9:31am

127 Views

Post# 32836751

RE:RE:RE:Profitable Debt-Free Cash-Rich CPH at 0.8x its EBITDA!!!

You probably can't read. The arbitrator is still deciding if, and if so how much, Cipher ows Bausch for misrepresenting (?, don't know we were never told the reason of why we lost the case) them regarding Trulance.

5, 10 million or even more? Anything goes.

<< Previous

Bullboard Posts

Next >>

Calibre discovers significant gold in Newfoundland